Gene and cell therapy startup raises £1.5m

Gene and cell therapy startup raises £1.5m

A University of Cambridge spinout developing a novel approach to improving gene and cell therapy performance has emerged from stealth with a pre-seed funding round [1]. Houdini Bio has raised close to £1.5 million in a funding round led by SCVC, the venture capital arm of Science Creates. 

 

Houdini Bio’s technology redesigns therapeutic DNA in order to bypass the defence mechanisms of the body. In this way, it enables treatments to remain active inside patients for longer and be administered at lower doses. 

 

These fundamental attributes mean it can overcome significant barriers to the long-term effectiveness and safety of treatment. According to Houdini’s pre-clinical data, it can increase gene expression more than tenfold in comparison to other existing methods. 

 

The funding raised in the round comprises both non-dilutive grant funding and pre-seed investment. It will be used to support the development of the startup’s machine learning-powered platform.

 

In addition to SCVC, the oversubscribed round included participation from Deep Science Ventures and Cambridge Enterprise VC.

 

Harry Destecroix, SCVC managing partner and Science Creates founder, commented: “Gene therapies really do represent the future of medicine, but they are stuck behind an invisible commercial and biological bottleneck. Houdini Bio has developed a compelling approach to overcoming one of the field’s most persistent challenges, and it’s great to have led this investment from SCVC.”

 

[1]: Houdini Bio secures £1.5m to improve gene and cell therapies

Get In Touch

If you have any questions for our medical sales recruitment agency team please call us on 01424 777745 or drop us an email at info@kirkhamyoung.co.uk – we're very happy to help.

Contact Us